Savara jumps on success of lung disease therapy in late-stage trial
26/06/2024 12:01
** Shares of therapy developer Savara SVRA.O rise 18.7% to
$4.57 premarket
** Co says its therapy molgramostim showed significant
improvement in a measure called DLCO in patients with autoimmune
pulmonary alveolar proteinosis (aPAP) when compared to placebo
** DLCO or Diffusing Capacity of the Lungs for Carbon
Monoxide, is a measurement to assess the lungs' ability to
transfer gas from inhaled air to the bloodstream
** aPAP is a rare autoimmune lung disease where patients may
have difficulty breathing
** SVRA plans to submit a marketing application for the
therapy in the first half of 2025
** Up to last close, stock down 19.2% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))